Abstract:The development of next-generation sequencing technology and the discovery of specific antibodies targeting chemically modified nucleotides have paved the way for a new era of epitranscriptomics. Cellular RNA is known to dynamically and reversibly undergo different chemical modifications after transcription, such as N<a class="workspace-trigger" href="#bib6">6</a>-methyladenosine (m6A), N<a class="workspace-trigger" href="#bib1">1</a>-methyladenosine (m1A), N<a class="workspace-trigger" href="#bib6">6</a>,2'-O-dimethyladenosine (m6Am), 5-methylcytosine (m5C), and 5-hydroxymethylcytidine (hm<a class="workspace-trigger" href="#bib5">5</a>C), whose identity and location comprise the field of epitranscriptomics. Dynamic post-transcriptional modifications determine the fate of target RNAs by regulating various aspects of their processing, including RNA export, transcript processing, splicing, and degradation. The most abundant internal mRNA modification in eukaryotic cells is m6A, which exhibits essential roles in physiological processes, such as embryogenesis, carcinogenesis, and neurogenesis. m6A is deposited by the m6A methyltransferase complex (composed of METTL3/14/16, WTAP, KIAA1429, and RBM15/15B), erased by demethylases (FTO and ALKBH5), and recognized by binding proteins (e.g., YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3). Liver is the largest digestive and metabolic organ, and m6A modifications play unique roles in critical physiological hepatic functions and various liver diseases. This review focuses on the biological roles of m6A RNA methylation in lipid metabolism, viral hepatitis, nonalcoholic fatty liver disease, liver cancer, and tumor metastasis. In addition, we summarize the existing inhibitors targeting m6A regulators and discuss the potential of modulating m6A modifications as a therapeutic strategy.

The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism

Noncoding RNAs in Alcoholic Liver Disease

New advances of DNA methylation in liver fibrosis, with special emphasis on the crosstalk between microRNAs and DNA methylation machinery

Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease

Epigenetic Modification in Alcohol‐related Liver Diseases

New advances of DNA/RNA methylation modification in liver fibrosis

[Epigenetics and Liver Fibrogenesis].

Alcohol and the mechanisms of liver disease

Histone Methylation Regulation as a Potential Target for Non-alcoholic Fatty Liver Disease

Gut microbiota induced epigenetic modifications in the non‐alcoholic fatty liver disease pathogenesis

Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease

Epigenetics of Autoimmune Liver Diseases: Current Progress and Future Directions

Analysis of Differentially Expressed Genes and Micrornas in Alcoholic Liver Disease

New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease

Epigenetic Modification in Alcohol Use Disorder and Alcoholic Cardiomyopathy: from Pathophysiology to Therapeutic Opportunities

Research Progress of mRNA Modification in Chronic Liver Disease

Epitranscriptomics in liver disease: Basic concepts and therapeutic potential

Epigenetic modification and hepatocellular carcinoma

The impact of epitranscriptomic modifications on liver disease

Epigenetics of Hepatocellular Carcinoma: a New Horizon.

Epigenetic modification of hepatitis B virus infection and related hepatocellular carcinoma